New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate
- Details
- Category: Novartis
New data demonstrated that antibodies induced by Novartis Vaccines investigational, four component, Meningococcal Serogroup B Vaccine (4CMenB) killed the majority of a collection of geographically and genetically diverse meningococcal serogroup B (MenB) strains.
Sanofi Pasteur's Dengue Vaccine in Final Stage of Clinical Development
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate(1,2), entered its first phase 3 clinical study in Australia.
Lilly CEO Calls for a 'Wave of Invention' to Reduce the Toll of Diabetes
- Details
- Category: Eli Lilly and Company
In a speech to the Cleveland Clinic Medical Innovation Summit, John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY) described the "paradox of progress" against diabetes, noting that "for all our progress in treating diabetes, our ultimate goal seems as far away as ever."
Pfizer Reports Third-Quarter 2010 Revenues of $16.2 Billion
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2010. Since the acquisition of Wyeth was completed on October 15, 2009, legacy Wyeth products and operations are reflected in the first three quarters of 2010, but not reflected in the first three quarters of 2009.
Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Early-Stage Oncology Compound
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today announced an innovative strategic partnership to co-develop BMS-817378, a preclinical small molecule MET/VEGFR-2 inhibitor.
Lundbeck expects to deliver solid profits during a period of new product launches and patent expiries
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) today announces the financial floor guidance for the company. The guidance addresses a period of transition for Lundbeck, but also a period where we will maintain our strong financial position.
Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin
- Details
- Category: Bayer
Bayer announced the preliminary results of the pivotal Phase III ROCKET AF study of rivaroxaban, the full details of which will be presented at the Late Breaker Session on November 15, 2010, at the Scientific Sessions of the American Heart Association (AHA) in Chicago, USA.
More Pharma News ...
- Nycomed to accelerate expansion in China
- Novartis drug Afinitor® approved by FDA
- GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal
- Sanofi-aventis to Acquire BMP Sunstone creating a Strong Consumer Healthcare Platform in China
- Merck KGaA Sells Théramex To Teva for EUR 265 million
- Bayer lifts sales and earnings again
- Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)